CareDx Reports Q3 2026 Financial Results and Raises Full-Year Guidance

CareDx reported Q3 2026 revenue of $139.4 million, above the FactSet consensus estimate of $122.0 million, and adjusted EPS of $0.70. Testing volume rose 51% year over year, while the adjusted EBITDA margin was 22%. The company raised its 2026 guidance, projecting revenue of $520 million to $530 million and adjusted EBITDA of $90 million to $100 million.